Clinical Trial Update: Neoadjuvant mFOLFOXIRI for Potentially Resectable Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring neoadjuvant mFOLFOXIRI for potentially resectable cholangiocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Drugs mentioned

• MFOLFOXIRI

Snippet

Sponsor: Khon Kaen University | Conditions: Cholangiocarcinoma | Phase 2 | Status: UNKNOWN